All In Biotech

Drug Trial Radar · NCT02970318

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator's Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects With R/R Chronic Lymphocytic Leukemia

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 310 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

310

Actual

Start

Feb 2, 2017

Primary completion

Sep 3, 2021

Study completion Oct 1, 2027

Sponsor

Lead sponsor
Acerta Pharma BVAstraZeneca (AZN)
Sponsor type
Industry
First posted
Nov 22, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to evaluate the efficacy of acalabrutinib compared with rituximab in combination with idelalisib or bendamustine in previously treated subjects with chronic lymphocytic leukemia (CLL).

Conditions

  • Chronic Lymphocytic Leukemia

Interventions

  • Acalabrutinib (ACP-196)Drug

    Acalabrutinib monotherapy

  • RituximabDrug

    Rituximab in combination with idelalisib or bendamustine

  • IdelalisibDrug

    Idelalisib in combination with rituximab

  • BendamustineDrug

    Bendamustine in combination with rituximab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS) Per Independent Review Committee (IRC) AssessmentTime frame: IRC assessments from randomization date until disease progression or death or IRC discontinuation on 15Jan2019 (as IA per this data cutoff showed crossing superiority boundary) whichever came first, up to 22 months of follow-up

Locations

157 sites in 25 countries. Site status is shown where the registry gives one.

  • Research Site

    Chandler, Arizona

  • Research Site

    Oxnard, California

  • Research Site

    Athens, Georgia

  • Research Site

    Joliet, Illinois

  • Research Site

    Cedar Rapids, Iowa

  • Research Site

    Mount Sterling, Kentucky

  • Research Site

    Saint Cloud, Minnesota

  • Research Site

    Lincoln, Nebraska

  • Research Site

    Brick, New Jersey

  • Research Site

    Nyack, New York

  • Research Site

    Canton, Ohio

  • Research Site

    Fort Sam Houston, Texas

  • Research Site

    Round Rock, Texas

  • Research Site

    Adelaide, Australia

  • Research Site

    Box Hill, Australia

  • Research Site

    Frankston, Australia

  • Research Site

    Geelong, Australia

  • Research Site

    Gosford, Australia

  • Research Site

    Hobart, Australia

  • Research Site

    Kogarah, Australia

  • Research Site

    Murdoch, Australia

  • Research Site

    Nedlands, Australia

  • Research Site

    South Brisbane, Australia

  • Research Site

    Woodville, Australia

  • Research Site

    Linz, Austria

  • Research Site

    Salzburg, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Wels, Austria

  • Research Site

    Antwerp, Belgium

  • Research Site

    Ghent, Belgium

  • Research Site

    Roeselare, Belgium

  • Research Site

    Yvoir, Belgium

  • Research Site

    Pleven, Bulgaria

  • Research Site

    Plovdiv, Bulgaria

  • Research Site

    Stara Zagora, Bulgaria

  • Research Site

    Vratsa, Bulgaria

  • Research Site

    Calgary, Canada

  • Research Site

    Montreal, Canada

  • Research Site

    Ottawa, Canada

Showing 40 of 157 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.